|
Nivolumab + Relatlimab Clinical Trials
6 actively recruiting trials across 6 locations
Also known as: BMS-986213, Opdualag
Pipeline
Phase 1: 2Phase 2: 4
Top Sponsors
- NYU Langone Health1
- Iovance Biotherapeutics, Inc.1
- H. Lee Moffitt Cancer Center and Research Institute1
- Exelixis1
- Carlo Contreras1
Indications
- Cancer6
- Metastatic Melanoma2
- Melanoma2
- Lung Cancer2
- Liver Disease1
Huntsville, Alabama1 trial
Pan Tumor Rollover Study
Local Institution - 0220
Phase 2
Phoenix, Arizona1 trial
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis Clinical Site #67
Phase 1
La Jolla, California1 trial
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
University of California, San Diego
Phase 2
Los Angeles, California1 trial
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
The Angeles Clinic at Cedars Sinai
Phase 2
Tampa, Florida1 trial
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Moffitt Cancer Center
Phase 2
Columbus, Ohio1 trial
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.